References
- Montgomery W, Ueda K, Jorgensen M, et al. Epidemiology, associated burden, and current clinical practice for the diagnosis and management of Alzheimer’s disease in Japan. Clinicoecon Outcomes Res. 2017;28(10):13–28.
- Ohara T, Hata J, Yoshida D, et al. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology. 2017;88(20):1925–1932.
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due toAlzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269.
- Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer’s disease. Am J Med. 2007;120(5):388–397.
- Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Engl J Med. 2018;378(4):321–330.
- Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated amyloid β. Alzheimers Dement. 2017;13(9):1004–1012.
- Salloway S, Sperling S, Fox NC, et al. Bapineuzumab 301 and 302 clinical trial investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–333.
- Wake T, Tabuchi H, Funaki K, et al. The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline. Int Psychogeriatr. 2018;30(5):635–639.
- Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873–2884.
- Japanese Society of Neurology. Chapter V: Alzheimer’s disease. Dementia disease treatment guidelines. 2010, Igakushoin, Tokyo.
- Lingler JH, Martire LM, Schulz R, et al. Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis. J Am Geriatr Soc. 2005;53(6):983–990.
- Clark CM, Sheppard L, Fillenbaum GG, et al. Variability in annual mini-mental state examination score in patients with probable Alzheimer disease: a clinical perspective of data from the consortium to establish a registry for Alzheimer’s disease. Arch Neurol. 1999;56(7):857–862.
- Gauthier S, Emre M, Farlow MR, et al. Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003;19(8):707–714.
- Arai H, Nakamura Y, Taguchi M, et al. Mortality risk in current and new antipsychotic Alzheimer’s disease users: large scale Japanese study. Alzheimers Dement. 2016;12(7):823–830.